Brokerages Set Replimune Group, Inc. (NASDAQ:REPL) Price Target at $16.20

Shares of Replimune Group, Inc. (NASDAQ:REPL) have received a consensus rating of “Buy” from the six ratings firms that are presently covering the stock, MarketBeat Ratings reports. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $16.80.

Several brokerages have recently issued reports on REPL. HC Wainwright reiterated a “buy” rating and issued a $17.00 target price on shares of Replimune Group in a research report on Monday, September 16th. Roth Capital raised Replimune Group to a “strong-buy” rating in a research note on Tuesday, August 27th. JPMorgan Chase & Co. boosted their price target on Replimune Group from $14.00 to $17.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 24th. Roth Mkm started coverage on Replimune Group in a research report on Tuesday, August 27th. They set a “buy” rating and a $17.00 price target for the company. Finally, Wedbush reiterated an “outperform” rating and issued a $16.00 target price on shares of Replimune Group in a research report on Thursday, June 6th.

Insiders Place Their Bets

In related news, CFO Emily Luisa Hill sold 8,938 shares of the company’s stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $10.18, for a total value of $90,988.84. Following the completion of the sale, the chief financial officer now owns 101,057 shares of the company’s stock, valued at $1,028,760.26. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 20.60% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Nisa Investment Advisors LLC increased its stake in Replimune Group by 10,304.2% during the second quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company’s stock worth $45,000 after acquiring an additional 4,946 shares during the last quarter. Point72 DIFC Ltd purchased a new position in shares of Replimune Group during the 2nd quarter worth $57,000. Quest Partners LLC purchased a new stake in Replimune Group in the 4th quarter valued at about $76,000. Diversified Trust Co acquired a new position in Replimune Group in the first quarter valued at about $94,000. Finally, China Universal Asset Management Co. Ltd. boosted its stake in Replimune Group by 72.8% during the first quarter. China Universal Asset Management Co. Ltd. now owns 11,808 shares of the company’s stock worth $96,000 after buying an additional 4,975 shares during the period. 92.53% of the stock is currently owned by institutional investors and hedge funds.

Replimune Group Stock Performance

NASDAQ REPL opened at $11.16 on Monday. The stock has a market capitalization of $762.45 million, a price-to-earnings ratio of -3.44 and a beta of 1.22. The stock has a 50-day moving average of $10.34 and a 200 day moving average of $8.51. The company has a current ratio of 13.46, a quick ratio of 13.46 and a debt-to-equity ratio of 0.16. Replimune Group has a twelve month low of $4.92 and a twelve month high of $17.14.

Replimune Group (NASDAQ:REPL) last announced its earnings results on Thursday, August 8th. The company reported ($0.78) earnings per share for the quarter, topping the consensus estimate of ($0.88) by $0.10. Sell-side analysts anticipate that Replimune Group will post -3.11 EPS for the current fiscal year.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.